in this issue
Regions :: Western Europe
Bayer HealthCare announces its biggest ever investment
7:44 AM MDT | March 13, 2014 | Natasha Alperowicz
Bayer says it will spend more than €500 million ($692.6 million) at its sites at Wuppertal and Leverkusen, Germany, to establish additional capacities to manufacture the recombinant factor VIII (rFVIII) hemophilia products that are currently in development. Bayer’s approved hemophilia A therapy product Kogenate FS/Kogenate is manufactured exclusively at Berkeley, CA. Establishing an additional supply source in Germany will help the company to prepare for production of the anticipated new therapy options and address the growing demand in this...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee